Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial
Lorenzo Guglielmetti, Uzma Khan, GE Velasquez, Maëlenn Gouillou, Nathalie Lachenal, Irene Motta, Francis Varaine, Carole D. Mitnick, et al. (9 authors)
Abstract
7 countries More than 18,000 visits conducted Kazakhstan 184 (24%) India 31 (4%) South-Africa 56 (7%) Georgia 13 (2%) Lesotho Peru 287 (38%) 81 (11%) Pakistan 101 (13%) Open label, Phase III, non-inferiority clinical trial Pulmonary tuberculosis (TB) with resistance to rifampicin and susceptibility to fluoroquinolones Participants aged 15 years No pregnancy, allergy or resistance to study drugs, severe lab abnormalities or cardiac risk factors 12 sites 754 participants
MeSH terms
- Tuberculosis
- Multiple drug resistance
- Medicine
- Clinical trial
- Internal medicine